{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:47:30Z","timestamp":1792036050459,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Exploratory Research in Clinical and Social Pharmacy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.rcsop.2026.100825","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:31:38Z","timestamp":1784302298000},"page":"100825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Metronidazole-associated mood changes: A case report"],"prefix":"10.1016","volume":"23","author":[{"given":"Lamis R.","family":"Karaoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"El Ouweini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid R.","family":"Karaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rcsop.2026.100825_bb0005","first-page":"397","article-title":"Therapeutic uses of metronidazole and its side effects: an update","volume":"23","author":"Hern\u00e1ndez Ceruelos","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.rcsop.2026.100825_bb0010","article-title":"Metronidazole. A therapeutic review and update","volume":"54","author":"Freeman","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.rcsop.2026.100825_bb0015","series-title":"Flagyl (Metronidazole) Package Insert. New York, NY","author":"Pfizer Inc.","year":"2025"},{"key":"10.1016\/j.rcsop.2026.100825_bb0020","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/j.1875-9114.1982.tb03216.x","article-title":"Mental confusion in a patient treated with metronidazole-a concentration-related effect?","volume":"2","author":"Schentag","year":"1982","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.rcsop.2026.100825_bb0025","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1176\/ajp.154.8.1170b","article-title":"Metronidazole-induced psychotic disorder","volume":"154","author":"Schreiber","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.rcsop.2026.100825_bb0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00004714-200202000-00012","article-title":"Antimicrobial-induced mania (antibiomania): a review of spontaneous reports","volume":"22","author":"Ahmed","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.rcsop.2026.100825_bb0035","first-page":"106","article-title":"Metronidazole-induced mania: recurrence with re-challenge","volume":"201","author":"Anita","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.rcsop.2026.100825_bb0040","doi-asserted-by":"crossref","first-page":"236","DOI":"10.12968\/hmed.2009.70.4.41632","article-title":"Organic psychosis induced by ofloxacin and metronidazole","volume":"70","author":"Koul","year":"2009","journal-title":"Br J Hosp Med (Lond)"},{"key":"10.1016\/j.rcsop.2026.100825_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rcsop.2026.100825_bb0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1752-1947-5-63","article-title":"Metronidazole-induced encephalopathy in a patient with infectious colitis: a case report","volume":"5","author":"Kim","year":"2011","journal-title":"J Med Case Reports"},{"key":"10.1016\/j.rcsop.2026.100825_bb0055","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00003088-199936050-00004","article-title":"Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials","volume":"36","author":"Lamp","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rcsop.2026.100825_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-018-9147-6","article-title":"Metronidazole-induced encephalopathy: a systematic review","volume":"267","author":"S\u00f8rensen","year":"2020","journal-title":"J Neurol"},{"issue":"suppl 1","key":"10.1016\/j.rcsop.2026.100825_bb0065","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1086\/647939","article-title":"Metronidazole is still the drug of choice for treatment of anaerobic infections","volume":"50","author":"L\u00f6fmark","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"10.1016\/j.rcsop.2026.100825_bb0070","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1007\/PL00022395","article-title":"Inhibition of monoamine oxidase by metronidazole","volume":"50","author":"Befani","year":"2001","journal-title":"Inflamm Res"},{"key":"10.1016\/j.rcsop.2026.100825_bb0075","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00004836-200304000-00024","article-title":"Metronidazole and mental confusion","volume":"36","author":"Mahl","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.rcsop.2026.100825_bb0080","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/WNF.0b013e3182334b35","article-title":"Metronidazole-induced central nervous system toxicity: a systematic review","volume":"34","author":"Kuriyama","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.rcsop.2026.100825_bb0085","first-page":"33","article-title":"Psychosis induced by cefuroxime and metronidazole","volume":"69","author":"Zahiruddin","year":"2014","journal-title":"Med J Malaysia"},{"key":"10.1016\/j.rcsop.2026.100825_bb0090","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.clinthera.2014.09.020","article-title":"Neurotoxicity with antimicrobials in the elderly: a review","volume":"36","author":"Mattappalil","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.rcsop.2026.100825_bb0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/PRA.0000000000000205","article-title":"Acute neuropsychiatric symptoms associated with antibiotic treatment of Helicobacter pylori infections: a review","volume":"23","author":"Neufeld","year":"2017","journal-title":"J Psychiatr Pract"},{"key":"10.1016\/j.rcsop.2026.100825_bb0100","article-title":"Antibiomania: a rare case of metronidazole-induced mania","volume":"13","author":"Puri","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.rcsop.2026.100825_bb0105","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/ejhpharm-2018-001677","article-title":"Metronidazole- and levofloxacin-induced psychotic disorders in chronic kidney patient","volume":"26","author":"Veli\u010dkovi\u0107-Radovanovi\u0107","year":"2019","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.rcsop.2026.100825_bb0110","first-page":"1012","article-title":"Possible association between metronidazole and agitated depression","volume":"100","author":"Voth","year":"1969","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.rcsop.2026.100825_bb0115","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.genhosppsych.2013.11.009","article-title":"Psychotic episode secondary to metronidazole use","volume":"36","author":"Khandheria","year":"2014","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.rcsop.2026.100825_bb0120","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1471-0528.1965.tb00106.x","article-title":"Attempted suicide with flagyl","volume":"72","author":"Lewis","year":"1965","journal-title":"J Obstet Gynaecol Br Commonw"},{"issue":"12","key":"10.1016\/j.rcsop.2026.100825_bb0125","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1093\/cid\/ciaa395","article-title":"Metronidazole-associated neurologic events: a nested case-control study","volume":"72","author":"Daneman","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.rcsop.2026.100825_bb0130","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1007\/s11606-023-08566-w","article-title":"Frequency and risk factor analysis for metronidazole-associated neurologic adverse events","volume":"39","author":"Lee","year":"2024","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.rcsop.2026.100825_bb0135","first-page":"1","article-title":"Influence factors of metronidazole-related CNS disorders: an analysis of the Japan adverse drug event report and FDA adverse event reporting system","author":"Takada","year":"2025","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"10.1016\/j.rcsop.2026.100825_bb0140","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.tips.2022.09.011","article-title":"Pharmacogenomics in treatment of depression and psychosis: an update","volume":"43","author":"Jukic","year":"2022","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.rcsop.2026.100825_bb0145","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.crad.2019.11.002","article-title":"Acute metronidazole-induced neurotoxicity: an update on MRI findings","volume":"75","author":"Patel","year":"2020","journal-title":"Clin Radiol"},{"issue":"5","key":"10.1016\/j.rcsop.2026.100825_bb0150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5414\/CPP39213","article-title":"Gender differences in the disposition of metronidazole","volume":"39","author":"Carcas","year":"2001","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.rcsop.2026.100825_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1435923","article-title":"Psychiatric disorders associated with fluoroquinolones: a pharmacovigilance analysis of the FDA adverse event reporting system database","volume":"15","author":"Xie","year":"2024","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.rcsop.2026.100825_bb0160","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkag083","article-title":"Fluoroquinolones and the risk of panic attacks: a systematic review and disproportionality analysis using individual case safety reports from the FDA adverse event reporting system (FAERS) database","volume":"81","author":"Raguram","year":"2026","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.rcsop.2026.100825_bb0165","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3390\/ph16081105","article-title":"Depressive and other adverse CNS effects of fluoroquinolones","volume":"16","author":"Wierzbi\u0144ski","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"10.1016\/j.rcsop.2026.100825_bb0170","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70036","article-title":"Association between oral fluoroquinolones and neuropsychiatric events: self-controlled case series with active comparator design","volume":"33","author":"Zhang","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Exploratory Research in Clinical and Social Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266727662600123X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266727662600123X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:17:52Z","timestamp":1792034272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266727662600123X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"alternative-id":["S266727662600123X"],"URL":"https:\/\/doi.org\/10.1016\/j.rcsop.2026.100825","relation":{},"ISSN":["2667-2766"],"issn-type":[{"value":"2667-2766","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metronidazole-associated mood changes: A case report","name":"articletitle","label":"Article Title"},{"value":"Exploratory Research in Clinical and Social Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcsop.2026.100825","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100825"}}